Nexocura: Non-Surgical Therapeutic to Accelerate Fracture Healing

Overview

Nexocura is developing an innovative RNA-based therapeutic platform to accelerate bone fracture healing. By targeting key molecular pathways involved in bone repair, Nexocura seeks to provide a non-surgical option for patients at high risk of poor recovery outcomes.

Learn more here.

The Issue

Each year, an estimated 178 million new fractures occur worldwide, and approximately 8% face healing complications within two years of injury. In patients with comorbidities such as aging,
diabetes, smoking, obesity, or osteoporosis, up to 50% of fractures heal poorly. Current therapies have not demonstrated meaningful improvements in fracture repair, leaving a critical need for an efficacious non-surgical approach to accelerate healing without serious adverse side effects.

Approach

Nexocura’s therapeutic platform leverages biomimetic RNA technology to effectively target a natural repair pathway Wnt and β-catenin signaling which plays a key role in how bones grow and mend after an injury. This strategy is designed to deliver timely tissue-specific activation that promotes healing.

MTM Student Engagement

MTM Students are focusing efforts on a strategic pathway for translation for Nexocura. A few checkpoints along the way include preclinical study, RNA technology optimization, regulatory strategy, stakeholder engagement, and most importantly, business plan. These will be supported by KOL surveys, grant applications, competitive analyses, investor pitch decks, and identification of commercial partners.